Simultaneously, glutaminolysis has been considered a hallmark of cancer and its increase in cancer cells has been associated with an upregulation of some amino acid transporters, particularly ASCT2, whose targeting may lead to promising anti-cancer treatments [5,14]. The gene discussed is SLC1A5; the disease is cancer.